Observational studyCritical care (London, England)2012
Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.
Observational study in Critical care (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Predictors of mortality in severe pneumonia patients: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.BMC infectious diseases · 2019Trial
- Trial
- Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.Tuberculosis and respiratory diseases · 2026Article
- Association between the glucose-to-platelet ratio and short-term and long-term all-cause mortality in critically ill patients with pneumonia: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Advanced oxidation protein products and ischemia-modified albumin as prognostic biomarkers of long-term mortality in community-acquired pneumonia: a prospective observational study.Scientific reports · 2026Observational
- Article
- Preventing pneumococcal infections in patients with hematological malignancies: a review of evidence and recommendations based on modified Delphi consensus.Frontiers in oncology · 2025Review
- Enzymatic Modulation of the Pulmonary Glycocalyx Enhances Susceptibility toAmerican journal of respiratory cell and molecular biology · 2024Article
- Meningitis in critically ill patients admitted to intensive care unit for severe community-acquired pneumococcal pneumonia.Annals of intensive care · 2023Article
- ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.Intensive care medicine · 2023Article
- Seasonal pattern in elderly hospitalized with acute kidney injury: a retrospective nationwide study in Italy.International urology and nephrology · 2022Article
- Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China.Emerging microbes & infections · 2022Article
- Electrochemical Detection for Isothermal Loop-Mediated Amplification of Pneumolysin Gene ofAnalytical chemistry · 2022Article
- Seasonal variation in the detection rate and all-cause in-hospital mortality of AKI in China: A nationwide cohort study.Frontiers in public health · 2022Article
- Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study.Annals of intensive care · 2021Article
- The expansive effects of polyamines on the metabolism and virulence of Streptococcus pneumoniae.Pneumonia (Nathan Qld.) · 2021Review
- Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis.Clinical kidney journal · 2021Article
- Seasonality of acute kidney injury in a tertiary hospital academic center: an observational cohort study.Environmental health : a global access science source · 2021Observational
- Meta-analysis of the effects of combination therapies of β-lactams and fluoroquinolones or macrolides in the treatment of community-acquired pneumonia.American journal of translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCommunity-acquired pneumonia (CAP) account for a high proportion of ICU admissions, with Streptococcus pneumoniae being the main pathogen responsible for these infections. However, little is known on the clinical features and outcomes of ICU patients with pneumococcal pneumonia. The aims of this study were to provide epidemiological data and to determine risk factors of mortality in patients admitted to ICU for severe S. pneumoniae CAP.
methodsWe performed a retrospective review of two prospectively-acquired multicentre ICU databases (2001-2008). Patients admitted for management of severe pneumococcal CAP were enrolled if they met the 2001 American Thoracic Society criteria for severe pneumonia, had life-threatening organ failure and had a positive microbiological sample for S. pneumoniae. Patients with bronchitis, aspiration pneumonia or with non-pulmonary pneumococcal infections were excluded.
resultsTwo hundred and twenty two patients were included, with a median SAPS II score reaching 47 [36-64]. Acute respiratory failure (n = 154) and septic shock (n = 54) were their most frequent causes of ICU admission. Septic shock occurred in 170 patients (77%) and mechanical ventilation was required in 186 patients (84%); renal replacement therapy was initiated in 70 patients (32%). Bacteraemia was diagnosed in 101 patients. The prevalence of S. pneumoniae strains with decreased susceptibility to penicillin was 39.7%. Although antibiotherapy was adequate in 92.3% of cases, hospital mortality reached 28.8%. In multivariate analysis, independent risk factors for mortality were age (OR 1.05 (95% CI: 1.02-1.08)), male sex (OR 2.83 (95% CI: 1.16-6.91)) and renal replacement therapy (OR 3.78 (95% CI: 1.71-8.36)). Co-morbidities, macrolide administration, concomitant bacteremia or penicillin susceptibility did not influence outcome.
conclusionsIn ICU, mortality of pneumococcal CAP remains high despite adequate antimicrobial treatment. Baseline demographic data and renal replacement therapy have a major impact on adverse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.